ARIAD Announces Reduction in U.S. Workforce as Part of Broad Program to Reduce Operating Expenses

11-11-2013 Business Wire HealthComments (0)

Ariad PharmaceuticalsIclusigPharmaceutical

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it is reducing approximately 40 percent of its staff positions in the United States following its decision to temporarily suspend the marketing and commercial distribution of Iclusig® (ponatinib) in the U.S. The reduction in U.S. staff includes positions in all major departments. This reduction in force is part of a broad program taken by ARIAD to significantly reduce its corporate operating expen

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top